Bruna Santos Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bruna Santos Souza has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bassam Janji
Luxembourg Institute of Health
1 shared publication - Eloah Rabello Suarez
Federal University of ABC
1 shared publication - Gabriela Lagreca
Center for Natural and Human Sciences, Federal University of ABC, Santo André 09210-580, SP, Brazil
1 shared publication - Ghanbar Mahmoodi Chalbatani
Department of Immunology, Mayo Clinic, Scottsdale, AZ 85259, USA
1 shared publication - Giselle Correia Próspero da Silva
Center for Natural and Human Sciences, Federal University of ABC, Santo André 09210-580, SP, Brazil
1 shared publication - Najla Santos Pacheco de Campos
Federal University of ABC
1 shared publication
Latest Publications
- Open Access
Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy
The carbonic anhydrase isoform IX (CAIX) enzyme is constitutively overexpressed in the vast majority of clear cell renal cell carcinoma (ccRCC) and can also be induced in hypoxic microenvironments, a major hallmark of most solid tumors. CAIX expression is restricted to a few sites in healthy tissues, positioning this molecule as a strategic target for cancer immunotherapy. In this review, we summarized preclinical and clinical data of immunotherapeutic strategies based on monoclonal antibodies (mAbs), fusion proteins, chimeric antigen receptor (CAR) T, and NK cells targeting CAIX against different types of solid malignant tumors, alone or in combination with radionuclides, cytokines, cytotoxic agents, tyrosine kinase inhibitors, or immune checkpoint blockade. Most clinical studies targeting CAIX for immunotherapy were performed using G250 mAb-based antibodies or CAR T cells, developed primarily for bioimaging purposes, with a limited clinical response for ccRCC. Other anti-CAIX mAbs, CAR T, and NK cells developed with therapeutic intent presented herein offered outstanding preclinical results, justifying further exploration in the clinical setting.
Open AccessCarbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy
The carbonic anhydrase isoform IX (CAIX) enzyme is constitutively overexpressed in the vast majority of clear cell renal cell carcinoma (ccRCC) and can also be induced in hypoxic microenvironments, a major hallmark of most solid tumors. CAIX expression is restricted to a few sites in healthy tissues, positioning this molecule as a strategic target for cancer immunotherapy. In this review, we summarized preclinical and clinical data of immunotherapeutic strategies based on monoclonal antibodies (mAbs), fusion proteins, chimeric antigen receptor (CAR) T, and NK cells targeting CAIX against different types of solid malignant tumors, alone or in combination with radionuclides, cytokines, cytotoxic agents, tyrosine kinase inhibitors, or immune checkpoint blockade. Most clinical studies targeting CAIX for immunotherapy were performed using G250 mAb-based antibodies or CAR T cells, developed primarily for bioimaging purposes, with a limited clinical response for ccRCC. Other anti-CAIX mAbs, CAR T, and NK cells developed with therapeutic intent presented herein offered outstanding preclinical results, justifying further exploration in the clinical setting.